Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 236
Tipo Título / Nombre Autor(es) Año
FLT3-ITP mutation characterization with classical PCR methodology versus capture and amplicon based NGS platforms: a PETHEMA NGS-AML project Bilbao C, Stuckey R..., Bergua Burgues JM 2023
Safety and efficacy of LP-108 as monotherapy and combined with azacitidine in patients with relapsed/refractory myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia Koenig K, Bergua Burgues JM, Montesinos P..., Curran E 2023
Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study Lancet J, Ravandi F, Monteseinos P..., Bergua Burgues JM 2023
Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML) González C, Simoes, Ariceta B, Martínez-Cuadron D..., Bergua Burgues JM 2023
The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial Mosquera Orgueira A, Pérez Encinas M, Díaz Arias JA..., Bergua Burgues JM 2023
Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial Mosquera Orgueira A, Pérez Encinas M, Díaz Arias JA..., Bergua Burgues JM 2023
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry Martínez-Cuadron D, Boluda B, Lorenzo Algarra J..., Bergua Burgues JM 2023
Clinical Features and Treatment in Patients Diagnosedwith Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema EpidemiologicRegistry (EPI-BLAS study) Navarro Vicente I, Lloret Madrid P. Solana-Altabella A..., Bergua Burgues JM 2023
A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial Bergua Burgues JM, Tarazona R, García Casado J, Gordillo JJ, Casas Aviles I, Rodríguez Veiga R, Cano I 2023
Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Olszewski AJ, Eradat H, Avigdor A, Horowitz NA..., Bergua Burgues JM 2023